🇺🇸 FDA
Pipeline program

INCLISIRAN SODIUM, BEMPEDOIC ACID, ATORVASTATIN, ROSUVASTATIN, EZETIMIBE

CKJX839A1DE02

Approved small_molecule active

Quick answer

INCLISIRAN SODIUM, BEMPEDOIC ACID, ATORVASTATIN, ROSUVASTATIN, EZETIMIBE for Hypercholesterolemia is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Hypercholesterolemia
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials